NEW YORK (360Dx) – Bruker today announced it has completed its acquisition of antibiotic-resistance and -susceptibility testing firm Merlin for an undisclosed amount.

Merlin, based in Bonn, Germany, will become Bruker's Center of Excellence for specialty biochemical and certain high-value MALDI Biotyper-based antibiotic-resistance and -susceptibility testing. The addition of Merlin expands Bruker's microbiology business, based on its MALDI Biotyper platform, Bruker said.